Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Pursuant to the terms of the transaction, Forbius’ non-TGF-beta assets were transferred to a newly formed private company which is being retained by Forbius’ existing shareholders.
Lead Product(s): AVID200
Therapeutic Area: Oncology Product Name: AVID200
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 21, 2020
Details:
Under this transaction, Bristol Myers Squibb would acquire Forbius’s TGF-beta program, including the program’s lead investigational asset, AVID200. TGF-beta is a key cytokine that regulates various cell processes, including regulation of the immune system.
Lead Product(s): AVID200
Therapeutic Area: Oncology Product Name: AVID200
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 24, 2020